CCM
TXG icon

CAAS Capital Management’s 10x Genomics TXG Stock Holding History

CAAS Capital Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-499,456
Closed -$62.3M – 924
2020
Q3 		$62.3M Sell
499,456
-48,460
-9% -$5.09M 1.45% 13
2020
Q2 		$48.9M Buy
+547,916
New +$42.7M 1.61% 12

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCAV
Meritech Capital Associates V Palo Alto, California $141M AUM 15.44% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
VMV
Venrock Management VI Palo Alto, California $47.6M AUM 45.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CAAS Capital Management's TXG Position: Q4 2020 in Review

CAAS Capital Management sold out of 10x Genomics (TXG) in Q4 2020, closing a stake of 499,456 shares — an estimated $62.3M sold.

CAAS Capital Management first reported a position in TXG in Q2 2020 and held it in 2 quarters. The position peaked at $62.3M in Q3 2020. 304 funds tracked by Wall St. Rank hold TXG as of Q4 2020.

  • CAAS Capital Management reported no remaining 10x Genomics position as of Q4 2020 after selling out during the quarter.
  • CAAS Capital Management sold 499,456 10x Genomics shares in Q4 2020, an estimated $62.3M.
  • CAAS Capital Management first reported a position in 10x Genomics in Q2 2020 and held it in 2 quarters.
  • CAAS Capital Management's 10x Genomics position peaked at $62.3M in Q3 2020.
  • 304 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2020.

Based on CAAS Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.